Lonza, a major Swiss contract development and manufacturing organization, has announced that its board of directors has appointed Daniel Palmacci (pictured above) as president of its Cell and Gene Division.
Mr Palmacci joins Lonza with more than 20 years of experience in the pharmaceutical industry, including senior positions at Novartis (NOVN: VX) and Bayer (BAYN: DE).
"We are positioned to consolidate our leading market position and maintain our focus on long-term success across both divisions"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze